Clinical laboratory tests remain the mainstay of decision making in medicine, but despite the rapid advances in genomic technologies, it’s still not possible to make informed decisions, based on a patient’s genetic makeup. Qatar’s national genomic project was one of the first in the Middle East to compare genomic sequence data with the Qatar Biobank which describes clinical data, making hitherto impossible connections between genetics and medical outcomes. This latest study aligned whole genome data from over 6000 individuals and 45 clinical traits to identify some 300 markers of medical risk that were clustered within the Qatari population (with comparisons also made with European, other African, and Japanese populations, with lower correlations)
One of the research team, Dr Omar Albagha, said: “The study provides new insights into the genetic architecture of clinical laboratory tests and identifies for the first time the genetic variations that are specific to the population of Qatar. The study also shows that findings from genetic studies in European populations don’t translate well when applied to our population in the Middle East. We are excited because the study represents a foundation for the implementation of precision medicine in the Middle East.”
Join the Fastest Growing Healthcare Market – Precision Med Expo Dubai 2021
Connect with healthcare providers & laboratories, distributors, investors, research bodies & government partners. Join the Middle East’s biggest precision medicine expo, in the fastest growing market.
Stay connected year-round by subscribing to PrecisionMed’s newsletter!
We are committed to providing you with a safe environment following all the health & safety guidelines set out by the local authorities. PrecisionMed Exhibition & Summit will deliver the event with strict standards of health & safety precautionary measures, including social distancing, contactless transactions, and hygiene protocols.
24-25 May 2022 | Conrad Dubai
The Middle East’s Dedicated Precision Medicine Exhibition & Summit.